IntraBio

The company's business model centers on identifying and developing novel drugs that address significant unmet medical needs. Its platform technologies are based on decades of research from institutions like the University of Oxford and the University of Munich, focusing on lysosomal function, autophagy, and neurology. IntraBio's lead drug, AQNEURSA™ (levacetylleucine), formerly IB1001, received FDA approval in September 2024 for treating neurological manifestations of Niemann-Pick disease Type C (NPC) in adults and certain pediatric patients. The company's pipeline also includes treatments for other rare lysosomal storage disorders such as GM2 Gangliosidosis (Tay-Sachs and Sandhoff Disease) and various forms of Ataxia. The company has received multiple Orphan Drug Designations and Fast Track designations from the FDA and European Medicines Agency (EMA), which provide benefits like market exclusivity and expedited review processes.

IntraBio generates revenue through the commercialization of its approved drugs. It has successfully raised significant capital to fund its clinical trials and commercial launch efforts, including a Series C round of over $40 million in 2023. The company operates with a lean team, focusing on efficiency and outsourcing functions like finance to partners to concentrate on its core competencies in drug development. By targeting orphan diseases, IntraBio can leverage programs like the FDA's Priority Review Voucher, which can be sold for substantial sums, providing a non-dilutive source of funding. The company has pursued a strategy of rapid development, taking its lead drug from development to FDA approval in approximately seven years.